Opakalim's epilepsy pivot shows striking OLE data, but MDD Phase 3 delay and ~3-quarter cash runway put the thesis on a tightrope

Bull

A positive RISE 3 readout demonstrating statistically significant reduction in focal seizure frequency versus placebo, consistent with the OLE's 54% responder rate and the differentiated tolerability profile (dizziness ≤5%, somnolence ≤5%), would confirm opakalim as a best-in-class Kv7.2/7.3 activator and support an NDA filing; this would also materially de-risk the cash runway concern by making the asset highly partnerable or by unlocking milestone-based financing, potentially including the Oberland Capital tranches tied to regulatory progress.

Bear

The most likely failure modes are an effect size in the randomized controlled trial that falls short of the OLE's open-label signal — a common pattern where OLE responder rates overestimate blinded efficacy — or a placebo responder rate high enough to dilute the treatment difference to non-significance; secondarily, if CNS tolerability worsens at scale relative to the OLE's low adverse event rates, differentiation versus competitors narrows sharply and the epilepsy pivot loses its commercial rationale.